We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Using real-world data (RWD) and real-world evidence (RWE) in clinical trials is growing in popularity among both industry and the FDA, but both groups agree that all stakeholders need to be on the same page when it comes to definitions and ways to measure results. Read More
The Trump administration pulled the plug last week on a rebate rule designed to lower drug costs — but Senate Finance Committee Chairman Chuck Grassley (R-Iowa) says a bipartisan package of reforms in the works will help shed light on pricing and rebates. Read More
The House Committee on Energy and Commerce voted Thursday in favor of amending the FAIR Drug Pricing Act of 2019, a bill that would require drug manufacturers to justify price increases to HHS. Read More
The FDA issued a draft guidance for trials of hormonal birth control products that makes recommendations regarding enrollment criteria, study elements, and safety and efficacy considerations. Read More